Google
Trusted Resources: News & Events
Latest announcements and gatherings
Bluebird Bio Presents Data From LentiGlobin Gene Therapy Trial
Bluebird Bio’s investigational gene therapy LentiGlobin safely prevents serious vaso-occlusive crises and acute chest syndrome in adolescents and adults with severe sickle cell disease (SCD), according to recent data from a Phase 1/2 clinical trial.
The findings, “Outcomes in patients treated with LentiGlobin for sickle cell disease (SCD) gene therapy: updated results from the Phase 1/2 HGB-206 group C study,” were recently presented at the virtual 25th European Hematology Association (EHA) Annual Congress.
“The promising results of this study, which show patients have an almost complete elimination of VOCs [vaso-occlusive crises] and ACS [acute chest syndrome], suggest LentiGlobin … has real potential to provide a significant impact for people living with sickle cell disease,” Julie Kanter, MD, said in a press release.
+myBinderRelated Content
-
Prevention of acute sickle cell crisis: review of the NEJM reportA recent article in the New England Jour...
-
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Depende...First patient with severe sickle cell di...
-
Mount Sinai receives NIH grant to study use of inhaled corticosteroids for sickle cell treatmentThe Departments of Emergency Medicine an...
-
Clinical trial offers hope to adults with sickle cell diseaseAt 33, Alexis Jones-Heggs has known a li...
-
Alabama Man Free of Sickle Cell After Gene Therapyhttps://www.youtube.com/watch?v=E9vYON8D...
-
NIH Launches new Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global ScaleThe National Institutes of Health plans ...
-
Sickle cell patient with severe anemia rapidly improves with voxelotor, case study showsGlobal Blood Therapeutics (GBT) reported...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
SomeBodyToTalkTo connects people affected by rare diseases with trusted resources, supportive communities, and opportunities to share their experiences.